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Objectives: The role of Pseudomonas aeruginosa in the long-term prognosis of chronic obstructive pul-
monary disease (COPD) is unknown. The purpose of this study was to determine whether P. aeruginosa is
associated with increased risk of exacerbations or death in patients with COPD.
Methods: This is a multiregional epidemiological study based on complete data on COPD outpatients
between 1 January 2010 and 31 October 2017 and corresponding microbiology and national register data.
Time-dependent Cox proportional hazards models and propensity matching was used to estimate
hospitalization-demanding exacerbations and death after 2 years, separately and in combination.
Results: A total of 22 053 COPD outpatients were followed for a median of 1082 days (interquartile-
range: 427e1862). P. aeruginosa was present in 905 (4.1%) patients. During 730 days of follow-up,
P. aeruginosa strongly and independently predicted an increased risk of hospitalization for exacerba-
tion or all-cause death (HR 2.8, 95%CI 2.2e3.6; p <0.0001) and all-cause death (HR 2.7, 95%CI 2.3e3.4; p
<0.0001) in analyses adjusted for known and suspected confounders. The signal remained unchanged in
unadjusted analyses as well as propensity-matched subgroup analyses. Among patients ‘ever colonized’
with P. aeruginosa, the incidence of hospital-demanding exacerbations doubled after the time of the first
colonization.
Conclusions: COPD patients in whom P. aeruginosa can be cultured from the airways had a markedly
increased risk of exacerbations and death. It is still not clear whether this risk can be reduced by offering
patients targeted antipseudomonal antibiotics. A randomized trial is currently recruiting patients to
clarify this (ClinicalTrials.gov: NCT03262142). J. Ekl€of, Clin Microbiol Infect 2020;26:227
© 2019 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
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According to the Global Burden of Disease Study, 3.2 million
people died from chronic obstructive pulmonary disease (COPD) in
2017 [1], and the burden of the disease continues to grow [2]. A
large part of the burden of COPD is associated with recurrent
exacerbation events which impair health status and worsen the
prognosis [3].
Pseudomonas aeruginosa has been reported to be present in the
airways in 4e20% of patients with acute exacerbation of COPD
[4e7]. Although the evidence is sparse and the methodology vari-
able, it has been suggested that P. aeruginosa is associated with
prolonged hospitalization, increased exacerbation rate and poor
long-term prognosis in COPD patients [8e10]. However, no defin-
itive conclusions regarding the clinical impact of P. aeruginosa in
COPD patients can be made since the bacterium is seen primarily in
advanced disease [6,11], which is in itself a strong predictor for poor
prognosis [12].
Thus, the aim of the current study was to evaluate whether
P. aeruginosa is independently associated with long-term adverse
outcomes in COPD patients. To address this, we conducted a
multiregional observational study with complete follow-up on the
investigated endpoints, and we performed multivariate regression
analyses and propensity score matching.Methods
Study design
This was a multiregional cohort study of COPD outpatients with
and without P. aeruginosa cultured from the lower respiratory tract.Data sources
Data from nationwide and regional administrative registries in
accordance with current Danish laws (Data Protection Agency:
2012-58-0004; The Danish National Committee on Health Research
Ethics: H-15010949). According to these laws, informed consent is
not required for registry-based studies. Linkage between registries
was done by using unique personal identification numbers, which
allows an exact linkage on individual level and ensures complete
follow-up [13].
Data were retrieved from the nationwide Danish Register of
Chronic Obstructive Pulmonary Disease (DrCOPD). The DrCOPD
holds individual data on all outpatient visits and hospital admis-
sions due to exacerbation of COPD, in patients aged 30 years or
above, at all Danish hospitals since 2008. Fig. 1 displays the inclu-
sion process. All patients who were registered with a visit to the
outpatient clinic between 1 January 2010 and 31 October 2017 in
the DrCOPD were included. Patients with malignant neoplasms
within 5 years prior to study entry were excluded since this con-
dition is strongly associated with mortality and may affect the
ability to interpret the results of the study exposure.
(Supplementary Table S1 lists the International Classification of
Disease 10th revision (ICD-10) codes used to define malignant
neoplasms.)
DrCOPD data were linked with microbiology data from the
Clinical Microbiology Departments in Eastern Denmark (Region
Zealand and Capital Region), with approximately 2.6 million in-
habitants. We defined the study population as COPD outpatients
with any microbiological data. All patients from Eastern Denmark
were included, regardless of microbiological status. Patients from
the western part of Denmark were not included since we could not
gain access to microbiological data for these patients. Study entryday was defined as the date for the patients first visit to the
outpatient clinic in the DrCOPD.
Patient characteristics
Patient characteristics were assessed at study entry. Information
was obtained from the DrCOPD and the Danish National Patient
Registry (DNPR). The DNPR holds data on all Danish in-hospital and
out-patient-clinic contacts since 1977 (Supplementary Table S2
lists the ICD-10 codes used to define comorbidities).
Pseudomonas aeruginosa status
Exposure was defined as any P. aeruginosa-positive culture
sample from the lower respiratory tract (i.e. sputum, tracheal
secretion, bronchial secretion and bronchial alveolar lavage) after
the study participant's entry date in the DrCOPD until end of
follow-up on 31 October 2017. Exposure date was defined as the
date of the first registered positive sample.
Outcome measures
The primary outcomes of this studywere (a) combined endpoint
of hospitalization for exacerbation or all-cause death, and (b) all-
cause death separately, respectively, after 2 years.
A secondary analysis was performed to estimate the separate
outcome of hospitalization for exacerbation after 2 years using a
competing risk model (Supplementary Table S7).
We chose to assess outcome after 2 years since we expected a
general low long-term survival rate in the study population based
on previous national [14] and international literature [15] on
mortality in COPD. Data on outcomes were retrieved from the
DrCOPD and DNPR. ICD-10 codes used to define exacerbation are
listed in Supplementary Table S3.
Statistical methods
A time-dependent Cox proportional hazard regression model
was developed to assess the risk between P. aeruginosa and
outcome. P. aeruginosawas included as a time-dependent variable,
taking time period as exposed within the first 2 years from study
entry into account. Change in status from unexposed to exposed
could only occur once, at the time for exposure date, and remained
unchanged during the remaining follow-up time. The Cox model
was adjusted for known and suspected cofounders assessed at
study entry based on previous literature in the field: age (contin-
uous), sex (male versus female), severity of airflow obstruction
based on percentage predicted forced expiratory volume in the first
second; forced expiratory volume (FEV1) (ordinal: 1e4), medical
research council dyspnoea scale (MRC) (ordinal: 1-5), body mass
index (BMI) (continuous), smoking status (active versus not active),
previous hospitalization for exacerbation of COPD within
12 months prior to study entry (yes versus no), inhaled cortico-
steroid; ICS (yes versus no) and calendar year for entry in DrCOPD
(ordinal: 2010e2017). Patients with unknown smoking status were
classified as non-active smokers. No forward or backward variable
selection was made. The models were tested for linearity of
continuous variables, proportion of hazards and interactions and
found to be valid.
A greedy-matched propensity score model [16] was applied as a
sensitivity analysis, forming a subpopulation of patients with
available microbiological data on culture samples from the lower
respiratory tract. The model used algorithms created and main-
tained by biomedical statisticians at the Mayo Clinic [17]. Patients
with P. aeruginosa-positive samples were matched (1:5 ratio) with
Fig. 1. Selection of study population: 22 053 patients registered with chronic obstructive pulmonary disease (COPD) in the Danish Register of Chronic Obstructive Pulmonary
Disease (DrCOPD) between 1 January 2010 and 31 October 2017.
J. Ekl€of et al. / Clinical Microbiology and Infection 26 (2020) 227e234 229patients who had never-positive-P. aeruginosa lower respiratory
tract samples using calendar year for study entry and the proba-
bility of being exposed to P. aeruginosa based on characteristics at
study entry: i.e. age, sex, FEV1% predicted, MRC, BMI, inhaled cor-
ticosteroids (ICS), smoking status and previous hospitalization for
exacerbation. In patients with unknown FEV1% predicted, MRC and
BMI at study entry, measurements from the first following outpa-
tient clinic visit were used. In the propensity matched population,
the risk estimates of P. aeruginosa were calculated by comparingoutcomes between the two matched groups by using a univariate
Cox proportional hazard model (i.e. Pseudomonas status: positive
versus negative). Sample date were set as exposure date in both
groups. The estimate was retested using a robust variance esti-
mator, accounting for the lack of independence in outcomes
induced by the matching.
A second propensity score model, inverse probability of treat-
ment weighting (IPTW) of propensity score [16], was additionally
performed as a sensitivity analysis (Supplementary Table S6A-C).
J. Ekl€of et al. / Clinical Microbiology and Infection 26 (2020) 227e234230Cox proportional hazard regression models are presented as
hazard ratios (HRs) with 95% confidence intervals (95%CIs). Cu-
mulative incidence plots are used to illustrate the cumulative
probability of exacerbation and death. Continuous variables are
presented as median values and interquartile ranges. Group com-
parisons were performed using non-parametric test (Wilcoxon
two-sample test) and t-test when appropriate. Categorical variables
are reported as frequencies and proportions and compared be-
tween groups using Fisher's exact test. A p 0.05 was considered
statistically significant. Statistical analyses were performed using
SAS statistical software 9.4 (SAS Institute Inc., Cary, NC, USA) and
statistical software R (version 3.4.3).Results
A total of 22 053 COPD outpatients were identified in the
DrCOPD between 1 January 2010 and 31 October 2017 (Fig. 1). Pa-
tients were followed for 1082 days (interquartile range: 427e1862).
The number of patients with P. aeruginosa was 905 (4.1%). Table 1
displays the characteristics of patients who were P. aeruginosa-
positive and P. aeruginosa-negative during the study period at the
time for inclusion into the study. The two groups were similar
overall, except for clinically relevant differences in lung function
capacity, frequency of hospital-demanding exacerbation for COPD
prior to study entry, prescribed corticosteroid inhalation medicine
and concurrent diagnoses of asthma and bronchiectasis. Follow-up
completion for study outcomes were 100% in both groups. Time toTable 1
Characteristics of the patients at study entry and by exposure to Pseudomonas aeruginos
All patients
n ¼ 22 053
(100%)
Demographics
Age, median (IQR) 69 (62e76)
Male, n (%) 9.868 (44.8
MRC, median (IQR) 3 (2e4)
Unknown MRC, n (%) 4.823 (21.9
FEV1% predicted, median (IQR) 49 (36e63)
Unknown FEV1%, n (%) 4.462 (20.2
BMI, median (IQR) 25 (21e29)
Unknown BMI, n (%) 4.704 (23.2
Smoking status, n (%):
Active 6.729 (30.5
Former ( 6 months) 599 (2.7)
Former (> 6 months) 9.694 (44.0
Never 594 (2.7)
Unknown 4.437 (20.1
Prescribed inhalation therapy, n (%):
Inhaled corticosteroids 15.851 (71.
Inhaled long-acting b2-agonist or long-acting muscarin antagonist 18.315 (83.





Inflammatory polyarthropathy 674 (3.1)
Systemic connective tissue disorder 566 (2.5)
Myocardial infarction 1.711 (7.7)
Atrial fibrillation 3.205 (14.5
Heart failure 3.607 (16.4
Hypertension 6.856 (31.2
Renal failure 960 (4.4)
Peripheral vascular disease 1.754 (8.0)
Cerebrovascular disease 2.099 (9.5)
Diabetes mellitus, type 2 2.654 (12.1
Asthma 3.216 (14.6
Bronchiectasis 249 (1.1)
IQR, interquartile range; MRC, Medical Research Council dyspnoea scale; BMI, body masinitial P. aeruginosa-positive sample was 649 days (interquartile-
range: 216e1278).Outcomes
Hospitalization for exacerbation or all-causes death (94% versus
48%, p <0.0001) and all-cause death separately (41% versus 17%, p
<0.0001) after 2 years occurred more frequently in P. aeruginosa-
positive patients than in patients without P. aeruginosa.
P. aeruginosa was associated with a significantly increased risk of
both outcomes in unadjusted analyses (HR 3.7, 95%CI 3.0e4.6, p
<0.0001 and HR 5.1, 95%CI 4.4e5.8, p <0.0001 respectively) and the
risk remained large and significant in the multivariable analyses
(Table 2). Fig. 2 illustrates the cumulative incidence.
In the P. aeruginosa-positive patients, the incidence rate of
hospital-demanding exacerbations substantially increased after the
first isolation of P. aeruginosa compared to before the isolation of
the bacterium (Fig. 3).Sensitivity analyses
A subgroup of 4679 patients with COPD were analysed in the
propensity matched model. This group consisted of 798
P. aeruginosa-positive patients (17%) matched 1:5 with 3881 pa-
tients (83%) with lower respiratory tract samples never positive for
P. aeruginosa (Supplementary Fig. S1). Patient characteristics of the






n ¼ 905 (4.1%) n ¼ 21.148 (95.9%)
71 (65e76) 69 (62e76) <0.0001
) 407 (45.0) 9.461 (44.7) 0.891
3 (3e4) 3 (2e4) <0.0001
) 173 (19.1) 4.650 (22.0)
39 (29e50) 49 (37e63) <0.0001
) 166 (18.3) 4.296 (20.3)
23 (20e27) 25 (21e29) <0.0001
) 171 (18.9) 4.533 (21.2)
<0.0001
) 242 (26.7) 6.487 (30.7)
10 (1.1) 589 (2.8)
) 470 (51.9) 9.224 (43.6)
21 (2.3) 573 (2.7)
) 162 (17.9) 4.275 (20.2)
9) 823 (90.9) 15.028 (71.1) <0.0001
0) 864 (95.5) 17.451 (82.5) <0.0001
1) 598 (66.1) 10.894 (51.5) <0.0001
9 (0.99) 121 (0.57) 0.115
16 (1.8) 658 (3.1) 0.018
30 (3.3) 536 (2.6) 0.161
77 (8.5) 1.634 (7.8) 0.375
) 134 (14.8) 3.071 (14.5) 0.810
) 147 (16.2) 3.460 (16.4) 0.963
) 273 (30.2) 6.583 (31.1) 0.558
38 (4.2) 922 (4.4) 0.934
66 (7.3) 1.688 (8.0) 0.490
77 (8.5) 2.022 (9.6) 0.325
) 106 (11.7) 2.548 (12.0) 0.794
) 187 (20.7) 3.029 (14.3) <0.0001
36 (4.0) 213 (1.0) <0.0001
s index (kg/m2); FEV1, forced expiratory volume in the first second.
Table 2
Cox regression hazard estimates for hospital-demanding exacerbation and all-cause death after 2 years with Pseudomonas aeruginosa as time-dependent variable
Hospitalization for exacerbation of COPD or all-cause death Unadjusted HR (95%CI) p-value Adjusted HR (95%CI) p-value
P. aeruginosa-positive 3.7 (3.0e4.6) <0.0001 2.8 (2.2e3.6) <0.0001
Hospitalization for exacerbation of COPD 12 months prior to study entry 2.1 (2.1e2.2) <0.0001 1.7 (1.7e1.8) <0.0001
MRC 1.5 (1.5e1.6) <0.0001 1.4 (1.3e1.4) <0.0001
Inhaled corticosteroid 1.6 (1.5e1.7) <0.0001 1.2 (1.2e1.3) <0.0001
Active smoking 1.0 (1.0e1.1) 0.730 1.2 (1.2e1.3) <0.0001
Age (per year) 1.03 (1.03e1.03) <0.0001 1.02 (1.02e1.02) <0.0001
Male 0.9 (0.9e1.0) 0.002 1.0 (1.0e1.0) 0.702
BMI (per unit increase) 0.98 (0.98e0.98) <0.0001 1.00 (0.99e1.00) 0.074
FEV1% predicteda 0.8 (0.8e0.8) <0.0001 0.8 (0.8e0.9) <0.0001
All-cause death Unadjusted HR (95%CI) P-value Adjusted HR (95%CI) P-value
P. aeruginosa-positive 5.1 (4.4e5.8) <0.0001 2.7 (2.3e3.4) <0.0001
Hospitalization for exacerbation of COPD 12 months prior to study entry 2.3 (2.2e2.5) <0.0001 1.6 (1.5e1.8) <0.0001
MRC 1.9 (1.9e2.0) <0.0001 1.6 (1.6e1.7) <0.0001
Active smoking 0.9 (0.8e0.9) <0.0001 1.4 (1.3e1.5) <0.0001
Male 1.0 (1.0e1.1) 0.175 1.2 (1.1e1.3) <0.0001
Age (per year) 1.07 (1.06e1.07) <0.0001 1.06 (1.05e1.06) <0.0001
BMI (per unit increase) 0.95 (0.94e0.95) <0.0001 0.97 (0.97e0.98) <0.0001
Inhaled corticosteroid 1.4 (1.3e1.5) <0.0001 0.8 (0.7e0.9) 0.0007
FEV1% predicteda 0.7 (0.6e0.7) <0.0001 0.7 (0.7e0.8) <0.0001
Sensitivity analysis: Cox regression hazard estimates for hospital-demanding exacerbation and all-cause death after 2 years with Pseudomonas aeruginosa as
time-dependent variable after excluding 249 patients with bronchiectasis.
Hospitalization for exacerbation of COPD or all-cause death Unadjusted HR (95%CI) p-value Adjusted HR (95%CI) p-value
P. aeruginosa-positive 3.3 (2.7e4.2) <0.0001 2.5 (1.9e3.3) <0.0001
All-cause death
P. aeruginosa-positive 5.2 (4.5e6.0) <0.0001 2.9 (2.4e3.5) <0.0001
MRC, Medical Research Council dyspnoea scale; BMI, body mass index; FEV1, forced expiratory volume in the first second.
The model is adjusted for calendar year for study entry and all variables displayed in the table.
Categorical variables are reported with one decimal place. Continuous variables are reported with two decimals.
a Increase in severity stage (1e4) of FEV1% predicted defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
J. Ekl€of et al. / Clinical Microbiology and Infection 26 (2020) 227e234 231P. aeruginosa-positive patients experienced significantly higher
rates of both hospitalization for exacerbation or all-cause death (89%
versus 77%, p <0.0001) and all-cause death separately (47% versus
37%, p <0.0001), and they had a numerically higher incidence of
exacerbations compared to P. aeruginosa-negative patients
(Supplementary Table S5). Although the estimates were somewhat
reduced,P. aeruginosa remained stronglyandsignificantlyassociated
with both study outcomes (HR 1.7, 95%CI 1.5e1.8, p <0.0001 and HR
1.4, 95%CI 1.3e1.6, p <0.0001 respectively). Supplementary Fig. S2
illustrates the cumulative incidence. The outcome signal remained
unchanged in the inverse probability of treatmentweighting (IPTW)
propensity score model (Supplementary Table S6A-C).
Lastly, the estimates for hospital-demanding exacerbation
remained high in the competing risk analysis in the main cohort
population (adjusted HR 2.7, 95%CI 2.1e3.5, p <0.0001) and pro-
pensity score subgroups (Supplementary Table S7).
Discussion
In this multiregional long-term follow-up epidemiological study
of COPD outpatients, we found a low prevalence of P. aeruginosa.
Patients with P. aeruginosa were substantially more likely to be
hospitalized for exacerbation of COPD or die of all causes compared
to those who never had this bacterial pathogen. Moreover, among
the patients who had P. aeruginosa isolated at any time, there was a
substantial increase in the incidence rate of hospital-demanding
exacerbations after the first isolation of P. aeruginosa compared to
before isolation of this bacterium. The result was robust for
adjustment for several known and suspected confounders and was
confirmed in propensity score sensitivity analyses using two
different models.
To our knowledge, this study is the largest study ever to inves-
tigate the prevalence of P. aeruginosa and the clinical implications ofcolonization with this bacterium in an unselected population of
COPD patients. Additionally, as compared with other research in
this field, the current study is the first to report complete long-term
follow-up on explored outcomes via nationwide registries.
Previous studies have primarily reported on smaller groups of
patients, and the risk of selection bias and information bias may
have been higher [4e11,18]. The prevalence of P. aeruginosa in our
study is considerable lower than that in most of these previous
studies [4,7,8], with reports of P. aeruginosa in up to 20% of the
patients [8]. Our study was performed using complete data from
the entire Eastern Denmark population during nearly 8 years.
Our finding that patients colonized with P. aeruginosa had poor
outcome is consistent with that of Almagro et al. [10], who found
P. aeruginosa to be an independent prognostic marker of 3-year
mortality in a prospective study of 181 patients hospitalized with
COPD exacerbation. In contrast, Boutou et al. [18] reported no as-
sociation between P. aeruginosa and long-term survival in COPD
outpatients in a smaller study (n ¼ 132); power issues may, at least
in part, explain that negative finding. Colonization with
P. aeruginosa plays an important role in the course of other chronic
lung diseases, in particular cystic fibrosis [19]. P. aeruginosa is also
associated with poor outcomes in patients with bronchiectasis, in
whom colonization with this bacterium has been reported to be
increased three-fold [20].
The completeness of data in the current study is a major
strength, allowing us to report long-term follow-up with high ac-
curacy in a well-characterized, large and unselected group of pa-
tients. Additionally, the diagnoses used for acute COPD
exacerbation and several of the comorbidities in the study have
been validated with high positive predictive values in the DNPR
(>90%) [21]. Moreover, use of robust and multiple acknowledged
statistical models, adjusting for important prognostic predictors,
further strengthens the internal data validity.
Fig. 2. Cumulative incidences of study outcomes. A. Hospitalization for exacerbation or all-cause death after 2 years. B. All-cause death after 2 years (red line: Pseudomonas
aeruginosa-positive patients, blue line: Pseudomonas aeruginosa-negative patients).
J. Ekl€of et al. / Clinical Microbiology and Infection 26 (2020) 227e234232Nevertheless, no definitive conclusions regarding causality
can be drawn based on our data due to the observational design.
Moreover, we hold no data on antibiotic utilization in the pop-
ulation. Thus, it is impossible to account fully for other possible
unknown confounders that could have affected the results.
However, the large study size and multiregional design makes
the results most likely to be generalizable to other COPD out-
patients inside and outside Denmark with similar COPD
characteristics.
Patients were included in the study based on the diagnosis of
COPD and any available microbiological data. Thus, P. aeruginosa-
positive patients could possibly be compared to patients where
respiratory cultures never were performed. This could beconsidered a limitation. However, the patients entered the study
at their first visit to the outpatient clinic, prior to and indepen-
dently of possible respiratory samples in both groups. Further-
more, our propensity score sensitivity analyses were based on a
subgroup of patients where data on respiratory cultures were
available.
We chose not to control for comorbidities since the major
diseases were evenly distributed between the groups. The slight
difference in concurrent asthma was controlled for by adjusting
for ICS in both the main and the sensitivity analyses. ICS was seen
to be strongly correlated to exacerbations. This is not surprising
since ICS is associated with increased risk of pneumonia and is
reserved for patients with more severe disease [22]. However, ICS
Fig. 3. Incidence of hospital-demanding exacerbation in 905 Pseudomonas aeruginosa-positive patients before and after isolation of P. aeruginosa (event/1000 days).
J. Ekl€of et al. / Clinical Microbiology and Infection 26 (2020) 227e234 233use did not appear to affect mortality. Few patients in our pop-
ulation had bronchiectasis. As a sensitivity analysis, we ran the
main regression model while excluding these and this did not
alter the signal.
The study addresses the prognostic role of P. aeruginosa in COPD,
and it reveals that this infrequent bacterium has a substantial as-
sociation with key outcomes, including exacerbations and mortal-
ity. Our study was not designed to address the mechanism
associated with these unwanted events. However, possible theories
include enhancement of airway inflammation, resulting in sus-
ceptibility to exacerbations and accelerated loss of lung function
[23e25]. P. aeruginosa is a well-established contributor to irre-
versible decline in lung function in cystic fibrosis, and the patho-
genesis is closely linked to well-studied and complex virulence
mechanisms, including a high genetic flexibility and biofilm for-
mation [19,26,27].
In conclusion, the long-term outcome, both in regard to death
and hospital-demanding exacerbations, was substantially worse in
those COPD patients colonized with P. aeruginosa. Further research
is needed to give a deeper understanding of the mechanism behind
these adverse clinical outcomes. And, most importantly, trial data
are needed to determine whether targeted Pseudomonas-active
antibiotic interventions can improve the prognosis in this highly
vulnerable group of patients. A randomized trial is currently
recruiting patients to clarify this (ClinicalTrials.gov: NCT03262142).Transparency declaration
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